Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launch of new drugs, including agents from Bayer and Boehringer Ingelheim, will generate robust 12% annual growth in the anticoagulant drug market over the next ten years.

A new Pharmacor study entitled Anticoagulants finds that the expected launches of Bayer's oral direct factor Xa inhibitor (rivaroxaban), and Boehringer Ingelheim's oral direct thrombin inhibitor (dabigatran etexilate) will address the pressing unmet need for safe and reliable oral anticoagulants.

"These agents have advantages over current treatments such as vitamin K antagonists because they offer more-predictable and consistent anticoagulation responses, and have convenient dosing regimens for chronic anticoagulation," said Nikhil Mehta, analyst at Decision Resources. "The choice of indication at which these agents are aimed will be critical to market value, and first- to-market status would give a significant advantage."

About Anticoagulants

Abnormal blood clot formation, or thrombosis, can diminish or block the flow of blood and oxygen to critical blood vessels in vital organs, leading to serious clinical conditions. Complications that can arise from thrombosis include acute coronary syndrome, acute ischemic stroke, and deep vein thrombosis/pulmonary embolism. The consequences of unwanted clot formation are increased risks of mortality and morbidity. Anticoagulants are used for both treatment and prevention of thrombosis.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Analyst Available to Comment on the FDA Approval of First-to-Market Agents for Type 2 Diabetes:

View Now